Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International ( (HK:6855) ) has issued an update.
Ascentage Pharma will present new preclinical data on four studies from its oncology pipeline at the 2026 American Association of Cancer Research Annual Meeting in San Diego. The presentations highlight promising combination strategies for its BCR-ABL inhibitor olverembatinib in endometrial carcinoma and mantle cell lymphoma, as well as enhanced antitumor activity from its FAK/ALK/ROS1 inhibitor APG-2449 and EED inhibitor APG-5918 in resistant tumor models.
The data underscore Ascentage Pharma’s efforts to position its candidates within cutting-edge combination regimens that target drug resistance and improve chemosensitivity in difficult-to-treat cancers. Showcasing these results at a major global cancer research forum may strengthen the company’s scientific profile, support future clinical development, and signal potential value creation opportunities for partners and investors in the oncology space.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a Hong Kong–listed biopharmaceutical company focused on developing innovative small-molecule therapies for cancer. Its pipeline includes targeted tyrosine kinase inhibitors and epigenetic modulators aimed at improving treatment outcomes in hematologic malignancies and solid tumors across global markets.
Average Trading Volume: 1,963,501
Technical Sentiment Signal: Hold
Current Market Cap: HK$17.33B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.